Page last updated: 2024-09-05

tolvaptan and dapagliflozin

tolvaptan has been researched along with dapagliflozin in 1 studies

Compound Research Comparison

Studies
(tolvaptan)
Trials
(tolvaptan)
Recent Studies (post-2010)
(tolvaptan)
Studies
(dapagliflozin)
Trials
(dapagliflozin)
Recent Studies (post-2010) (dapagliflozin)
9671727861,4783681,407

Protein Interaction Comparison

ProteinTaxonomytolvaptan (IC50)dapagliflozin (IC50)
Sodium/glucose cotransporter 1Homo sapiens (human)1.1661
Sodium/glucose cotransporter 2Homo sapiens (human)0.0022
Sodium/myo-inositol cotransporter 2Homo sapiens (human)0.38
Solute carrier family 5 member 4Homo sapiens (human)0.0014

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Akimoto, T; Imai, T; Maeshima, A; Masuda, T; Miki, A; Miyazawa, Y; Murakami, T; Muto, S; Myoga, A; Nagata, D; Nakagawa, S; Ohara, K; Okada, M; Saito, O; Sekiguchi, C; Sugase, T; Yoshizawa, H1

Other Studies

1 other study(ies) available for tolvaptan and dapagliflozin

ArticleYear
Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan.
    Nephrology (Carlton, Vic.), 2019, Volume: 24, Issue:9

    Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzhydryl Compounds; Body Composition; Female; Fluid Shifts; Furosemide; Glucosides; Humans; Male; Prospective Studies; Renal Insufficiency, Chronic; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Tolvaptan; Treatment Outcome; Water-Electrolyte Balance; Water-Electrolyte Imbalance

2019